Cancer Research

Multiple myeloma
#HaemaLogiX #Immunotherapy #Myeloma #Oncology

Redefining targeted immunotherapy in multiple myeloma through antigen innovation

Dr Rosanne Dunn, Co-Founder and Chief Scientific Officer at HaemaLogiX, explores how discovery of a new class of tumour‑specific antigens is transforming how we treat plasma cell dyscrasias. For more than two decades, progress in multiple myeloma has been marked by sustained advances in drug development that have not translated… Read More

#Cancer Research #Exclusive Content

#Antibiotics #Clinical trial

Fungus-derived compounds could treat aggressive cancer 

Researchers have identified chemical compounds derived from a fungus that could help treat an aggressive cancer, the Journal of Antibiotics reports.  The compounds, named paramyfurans A and B and paramylactone, were extracted from a fungal strain called Paramyrothecium sp. BF-1049. They were tested against three mesothelioma cell lines in a laboratory setting, with… Read More

#Cancer Research #Editor's Choice #News

#Francis Crick Institute #Lung cancer #Oncology #University College London

New research suggests anti-IL-1β drugs could prevent lung cancer

Researchers at the Francis Crick Institute and University College London (UCL) have identified a 14-protein signature in the blood that could identify who would benefit from cancer prevention drugs.  The signature enabled the team, funded by Cancer Research UK and the European Research Council (ERC), to predict… Read More

#Cancer Research #Editor's Choice #News

Tumour microenvironment
#Cancer research #Cervical cancer #Colorectal cancer #Head and neck cancer

Drug could reduce tumours by 55%, results show 

An experimental drug could shrink tumours by up to 55%, results show.  GRWD5769, developed by biotech company Greywolf Therapeutics, is a first-in-class oral small molecule inhibitor of Endoplasmic Reticulum Aminopeptidase 1 (ERAP1), an enzyme that regulates tumour antigen presentation on MHC-I.  The drug works by… Read More

#Cancer Research #News

#Breast cancer #Genetics / genomics #Oncology #Precision medicine #University College London

Gene test guides more personalised breast cancer treatment

Many people with breast cancer can safely avoid chemotherapy with the use of a gene test, a large international clinical trial led by University College London (UCL) has found.  The OPTIMA trial (Optimal Personalised Treatment of early breast cancer using Multi-parameter Analysis) followed more than 4,400 patients… Read More

#Cancer Research #News

Human brain
#Cancer research #Gene therapy #Trogenix

First patient dosed in glioblastoma gene therapy trial 

The first patient has been dosed in the Phase I/II clinical trial of a gene therapy for glioblastoma (GBM).  TGX-007, developed by oncology company Trogenix, is a dual-payload adeno-associated virus (AAV)-based gene therapy.   TGX-007 harnesses Trogenix’s proprietary Synthetic Super-Enhancer (SSE) technology to exploit the core cancer cell identity. The… Read More

#Cancer Research #News

#Affibody #Breast cancer #Radioligand Therapies (RLTs)

Affibody to reveal data from first-in-human cancer trial 

First-in-human data from a study into a radioligand therapy (RLT) targeting metastatic breast cancer is set to be announced.  Radiopharmaceutical company Affibody will present the data on ABY-271, the HER2-targeting RLT candidate, at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2026 Annual Meeting. The event will… Read More

#Cancer Research #News

Fast track concept
#Accelerated assessment #Oncology #Osteosarcoma #Paediatrics #Regulatory

The case for accelerated approval in recurrent osteosarcoma

Introduction In an age where novel biotechnology products are being developed on a much larger and more rapid scale at significantly higher costs and risks than ever before, it is important that this urgency is maintained through to patient access. Owing to the broad reach and the mass adoption of… Read More

#Cancer Research #Exclusive Content #Regulatory

Colorectal cancer
#Cancer research #Colorectal cancer #Genetic profiling

Genetic pattern key to colorectal cancer, research shows 

A genetic pattern could explain how colorectal cancer develops, new research suggests.  Findings from ChristianaCare’s Helen F Graham Cancer Center & Research Institute identified a developmental genetic pattern that helps explain how colorectal cancer develops, why it becomes aggressive and how long patients are likely to survive.  The study, published… Read More

#Cancer Research #News

Soft tissue sarcoma
#Clinical trial #RNA modifying enzymes #Sarcoma

Enzyme inhibitor shows early evidence of treating sarcoma 

An RNA-modifying enzyme inhibitor has shown positive results in treating sarcoma patients during a Phase I trial.  STC-15, developed by STORM Therapeutics, demonstrated a disease control rate of 54% at 12 weeks and a median progression-free survival of six months. The trial enrolled 42 patients with advanced… Read More

#Cancer Research #News

#Cancer research #Gut microbiome #Immuno-oncology #Melanoma #Non-small cell lung cancer (NSCLC)

Improving response: Microbiome-based approaches to checkpoint inhibitor resistance

Sheri Simmons, Acting Chief Scientific Officer at MaaT Pharma, explores how a diversified gut microbiome could improve the treatment of cancer.   Harnessing the microbiome is emerging as a promising strategy to enhance the body’s response to certain anti-cancer therapies and to mitigate treatment-related toxicities (1). Clinical evidence indicates that gut microbiome composition contributes to patient… Read More

#Cancer Research #Exclusive Content

#Cancer research #Medicines Discovery Catapult #Nuclear medicine #Radiopharmaceuticals #UK

Is the UK set to become a radiopharma leader?

The latest episode of the DDW ‘In Conversation With’ series is available to listen to below. This week, Bruno Quinney speaks to Dr Juliana Maynard, Head of Translational Imaging at Medicines Discovery Catapult. MDC recently announced a partnership with the UK National Nuclear Lab, and Maynard’s… Read More

#Cancer Research #Featured Podcasts #Podcasts

Medical laboratory
#Bispecific Antibodies #Cancer research #Clinical trial

Mestag doses first patient in treatment for solid tumours 

Mestag Therapeutics has dosed the first patient in its Phase I trial evaluating a novel therapeutic strategy to treat solid tumours.  MST-0312 is a bispecific antibody designed to activate lymphotoxin-beta receptor (LTBR) in the tumour microenvironment to induce the formation of tertiary lymphoid structures (TLS) and associated high… Read More

#Cancer Research #News

Lung cancer
#Cancer research #Lung cancer #The Francis Crick Institute

Nervous system crucial in lung cancer response, research shows 

Regulating the nervous system could be crucial in the response to lung cancer, new research suggests.   Researchers at the Francis Crick Institute have revealed that sensory nerve signals interfere with the immune system’s response to lung cancer, highlighting a previously unrecognised neuroimmune connection which could be targeted… Read More

#Cancer Research #Editor's Choice #News